Krystal Biotech, Inc.

KRYS

$369.23

+1.48%

2026-09-02 16:00:01 EDT+$5.39

Healthcare

Biotechnology

NASDAQ

Active Trading

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United ...

Price Action of KRYS

$369.23

+1.48%+$5.39

High—

Low—

52W High-3.5%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, founded in 2015/2016. The company specializes in developing redosable gene therapies using its proprietary herpes simplex virus (HSV) vector platform. Its lead product, Vyjuvek (beremagene geperpavec), received FDA approval in May 2023 for the treatment of ...Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, founded in 2015/2016. The company specializes in developing redosable gene therapies using its proprietary herpes simplex virus (HSV) vector platform. Its lead product, Vyjuvek (beremagene geperpavec), received FDA approval in May 2023 for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. In 2024, the company reported revenue of $439 million from Vyjuvek sales, indicating successful commercialization. Beyond DEB, the pipeline includes KB105 for autosomal recessive congenital ichthyosis (Phase I/II), KB301 for aesthetic dermatology (Phase I/II), and preclinical programs for cystic fibrosis (KB407) and Netherton syndrome (KB104). The company is also developing earlier-stage candidates for chronic skin conditions and multiple aesthetic indications. Financially, Krystal Biotech maintains a strong balance sheet with over $1 billion in cash and investments. Its profitability metrics are robust: gross profit margin of 93.3%, operating margin of 48.4%, and net margin of 54.8%. The company employs 295 people and is led by CEO Krish S. Krishnan, with co-founder Suma Krishnan serving as President. The leadership team has deep biotech expertise, with prior experience in successful IPOs. The company's unique commercialization model and rapid manufacturing capabilities distinguish it in the gene therapy space. Krystal Biotech continues to expand its pipeline and geographic reach, aiming to address high unmet medical needs in genetic diseases and beyond. With a market cap exceeding $9 billion and a price-to-earnings ratio of about 39, the company is positioned for continued growth in the gene therapy market.ExpandCollapse

Founded

2016

Employees

295

CEO

Krish S. Krishnan

Full Name

Krystal Biotech, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

19.34%

Market Cap

$10.88B

Current Ratio

8.32

WACC

7.05%

ROIC

20.80%

Contact Information

https://www.krystalbio.com

412 586 5830

2100 Wharton Street, Pittsburgh, PA 15203

Key Metrics of KRYS

Snapshot

Latest / TTM · 6 periods

Market Cap

$10.88B

ROCE

14.4%

EV / EBITDA

48.22x

+1.3% YoY

FCF Yield

2.4%

-0.3% YoY

Cash Conversion Cycle

600.2d

Current Ratio

8.32

Quick take

TTM —

Positive CCC

Financial Highlights of KRYS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

93.3%

Net Margin

54.8%

P/E Ratio

44.92x

n/a

Debt / Equity

0.01

n/a

Current Ratio

8.32

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of KRYS

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $1.87 · Revenue $129.65M · 7 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $2.11 · Revenue $142.82M · 6 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $7.62 · Revenue $507.98M · 8 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $2.23 · Revenue $143.38M · 2 analysts

Recent history

Aug 3, 2026
Q2 FY2026 · Results reported
EPS $1.79 · Revenue $119.22M
View filing
May 4, 2026
Q1 FY2026 · Results reported
EPS $1.83 · Revenue $116.36M
View filing
Feb 17, 2026
FY2025 · Annual results
EPS $6.84 · Revenue $389.13M
View filing
Nov 3, 2025
Q3 FY2025 · Results reported
EPS $2.66 · Revenue $97.80M
View filing
Aug 4, 2025
Q2 FY2025 · Results reported
EPS $1.29 · Revenue $96.04M
View filing
May 6, 2025
Q1 FY2025 · Results reported
EPS $1.20 · Revenue $88.18M
View filing

Financial Statements of KRYS

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$389.1M	+33.9%	+2.5%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$204.8M	+129.7%	-2.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+92.6%	-0.5%	+0.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+41.5%	+83.3%	+6.2%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+52.6%	+71.5%	-4.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$188.9M	+58.5%	-2.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+48.5%	+18.3%	-5.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.8%	-0.2%	-8.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	9.95x	+36.8%	-12.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$1.3B	+26.3%	+7.4%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	6.84 vs 6.75	+1.3%	1.79 vs 1.70	+5.2%
Revenue Surprise	$389.1M vs $387.6M	+0.4%	$119.2M vs $120.9M	-1.4%

Insider Transactions of KRYS

Acquisitions (A)

Since Jun 25, 2026

Disposals (D)

Since Jun 25, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 14, 2026	ROSSI DINO A	director	Common Stock	D	3,691	—
Aug 14, 2026	ROSSI DINO A	director	Common Stock	D	341	$325.60
Aug 14, 2026	ROSSI DINO A	director	Common Stock	D	2,287	$326.60
Aug 14, 2026	ROSSI DINO A	director	Common Stock	D	5,226	$327.39
Aug 14, 2026	ROSSI DINO A	director	Common Stock	D	1,687	$328.52

Earnings Call Transcript of KRYS

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Thank you for standing by, and welcome to the Krystal Biotech 2Q 2026 Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to hand the conference over to your host, Stephane Paquette, Senior Vice President of Corporate Development. Please begin. Stephane Paquette: Good morning, and thank you all for joining today's call. Earlier today, we released our financial results for the second quarter of 2026. The press release is available on our website at www.krystalbio.com. We also filed our earnings 8-K and 10-Q with the SEC earlier today. Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Laurent Goux, Executive Vice President and General Manager for Europe, Christine Wilson, Senior Vice President and Head of U.S. Commercial; and Kate Romano, Chief Accounting Officer. This conference call will and our responses to questions may contain forward-looking statements. You are cautioned not to rely on these forward-looking statements, which are based on current expectations using information available as of the date of this call and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties and other factors can be found in our SEC filings. With that, I will turn the call over to Krish. Krish Krishnan: Good morning, and thank you for joining us. We were focused on execution in Q2, making solid progress across both our commercial and clinical programs. Internationally, strong underlying demand and high patient excitement underpin our launch. We're working diligently to meet that demand and broaden access for DEB patients around the world. We're advancing pricing and reimbursement discussions in Germany, France, Italy, Spain and the U.K., while working through the country-specific requirements associated with each launch. In the United States, demand continues to grow, supported by our increasing focus on reaching patients and physicians in the community setting. Laurent and Christine will provide additional detail on our commercial performance and international launch progress. Our clinical pipeline is also advancing across multiple important programs. We currently have 2 registrational studies underway, our study in neurotrophic keratitis and our study of ocular lesions in patients with dystrophic epidermolysis bullosa. In addition, our repeat dose studies in cystic fibrosis and Hailey-Hailey disease are progressing. And assuming supportive data, we believe both programs have the potential to advance into registrational development in 2027. We're also making great progress with our KB707 program in oncology. Our inhaled 707 formulation for the treatment of NSCLC is on track for a registrational study next year. And we are now evaluating our intratumoral KB707 formulation in Gorlin syndrome, …

Leadership Team of KRYS

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Krish S. Krishnan	Founder, Chairman, President & Chief Executive Officer	USD 1,662,567	Male	1965	Active
Suma Krishnan	Founder, President of R&D and Director	USD 1,106,423	Female	1965	Active
Kathryn A. Romano	Executive Vice President & Chief Accounting Officer	USD 674,756	Female	1982	Active
David Chien	Senior Vice President of Clinical Development	—	Male	—	Active
Josh Suskin	Senior Director & Head of US Human Resources	—	Male	—	Active
Laurent Goux	Executive VP & Head of International	—	Male	1975	Active
John Thomas	EVP, General Counsel & Corporate Secretary	—	Male	1974	Active
John Karakkal	Vice President of North American Sales & Marketing	—	Male	—	Active
Christine Wilson	Senior VP & Head of US Commercial	—	Female	—	Active
Stephane Paquette	Senior Vice President of Corporate Development	—	—	—	Active

Recent News of KRYS

Zacks Investment Research23 hours agoNeutral

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.

GlobeNewsWireyesterdayNeutral

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.

Zacks Investment ResearchyesterdayNeutral

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

247 Wallst8/14/2026Neutral

Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.

Zacks Investment Research8/4/2026Neutral

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

Historical Employee Count of KRYS

Current

295

Change

+7.27%

Minimum

119

Maximum

295

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	295	10-K	Feb 17, 2026	View
Dec 31, 2024	275	10-K	Feb 19, 2025	View
Dec 31, 2023	229	10-K	Feb 26, 2024	View
Dec 31, 2022	210	10-K	Feb 27, 2023	View
Dec 31, 2021	119	10-K	Feb 28, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Krystal Biotech, Inc.